Cancer Treatment News and Research

RSS

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Cornerstone Pharmaceuticals, Inc., a clinical stage company and leader in the growing field of cancer metabolism-based therapeutics, today announced the initiation of a Phase I clinical trial assessing the safety and efficacy of escalating doses of CPI-613, in combination with bendamustine and rituximab, in patients with relapsed or refractory B-cell Non-Hodgkin lymphoma (NHL).

8 Dec 2014

Scientists discover new line of defence that cancer cells use to evade cell death

Cancer Research UK scientists have discovered a new line of defence used by cancer cells to evade cell death, according to research published in Nature Communications today (Monday).

8 Dec 2014

Most elderly women with early-stage breast cancer still receive radiation therapy despite less benefit

Women over the age of 70 who have certain early-stage breast cancers overwhelmingly receive radiation therapy despite published evidence that the treatment has limited benefit, researchers at Duke Medicine report.

8 Dec 2014

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

AbbVie presented during an oral presentation at the American Society of Hematology's 56th Annual Meeting new results from a Phase 2 study of investigational compound venetoclax (ABT-199/GDC-0199) in patients with acute myelogenous leukemia (AML). AML is an aggressive and deadly type of blood cancer, in which the body produces too many of a specific type of white blood cell (myeloblast), which can crowd out healthy blood cells.

8 Dec 2014

Innovative cell therapy shows highly promising results in pediatric patients with ALL

An innovative cell therapy against a highly aggressive form of acute lymphoblastic leukemia (ALL) continues to show highly promising results in children treated in a pilot study. Ninety-two percent of the 39 children receiving bioengineered T cells had no evidence of cancer at one month after treatment, with this complete response persisting in some cases for more than two years.

7 Dec 2014

New light-triggered strategy can provide accurate control over aptamer-based therapeutics

While aptamers—single-stranded nucleic acids—offer promise as drug-delivery tools for cancer treatment, it has proven difficult to get them to tumor cells at therapeutic levels.

4 Dec 2014

Myriad Genetics to highlight clinical data from three Prolaris studies at SUO 2014

Myriad Genetics, Inc. today announced that clinical data from three studies with Prolaris in prostate cancer patients will be highlighted at the 2014 Society of Urologic Oncology Annual Meeting being held tomorrow in Rockville, Md. The new data show that the Prolaris test could save the healthcare system $6 billion over 10 years and that physicians are using the test appropriately to personalize treatment options for their patients.

3 Dec 2014

Maternal age and successful egg freezing with PGS: an interview with Dr. Santiago Munné

The leading cause of of pregnancy loss or infertility is chromosomal abnormality or imbalance, where extra genetic material is present or some is missing - what’s called aneuploidy. This imbalance leads to the inability to produce viable embryos or pregnancy.

2 Dec 2014

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Novartis will highlight more than 250 abstracts demonstrating advances in blood and breast cancer research at the upcoming American Society of Hematology (ASH) annual meeting December 6-9, and CTRC-AACR San Antonio Breast Cancer Symposium (SABCS) December 9-13.

2 Dec 2014

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

National guidelines recommend that men with low- and intermediate -risk prostate cancer and life expectancies of less than 10 years should not be treated with radiation or surgery, since they are unlikely to live long enough to benefit from treatment. Yet it is unknown whether such men are unnecessarily receiving these aggressive local treatments, putting them at risk for potentially debilitating side effects.

2 Dec 2014

Dresden scientists get access to the World's second-fastest computer for cancer research

For their calculations, researchers at the Helmholtz-Zentrum Dresden-Rossendorf will now, starting in 2015, have access to the World's second-fastest computer. The Dresden research initiative is one of 56 projects the US Department of Energy has granted access to Titan as part of their INCITE program.

27 Nov 2014

Researchers use EHRs to uncover hidden drug benefits

With research and development costs for many drugs reaching well into the billions, pharmaceutical companies want more than ever to determine whether their drugs already at market have any hidden therapeutic benefits that could warrant putting additional indications on the label and increase production.

27 Nov 2014

TET1 enzyme may be important target for cancer diagnostics, treatment

Mutations in the KRAS gene have long been known to cause cancer, and about one third of solid tumors have KRAS mutations or mutations in the KRAS pathway. KRAS promotes cancer formation not only by driving cell growth and division, but also by turning off protective tumor suppressor genes, which normally limit uncontrolled cell growth and cause damaged cells to self-destruct.

27 Nov 2014

New research brings personalized cancer vaccine approach one step closer to reality

In the near future, physicians may treat some cancer patients with personalized vaccines that spur their immune systems to attack malignant tumors. New research led by scientists at Washington University School of Medicine in St. Louis has brought the approach one step closer to reality.

27 Nov 2014

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Scientists from Queen Mary University of London have made a breakthrough in developing a new therapy for advanced bladder cancer - for which there have been no major treatment advances in the past 30 years.

26 Nov 2014

Gamma Medica to offer Philips MicroDose SI as complement to LumaGEM MBI system

Gamma Medica today announces the company will now offer Philips MicroDose SI, the first full-field digital mammography (FFDM) system that supports single-shot, non-invasive spectral imaging, as a complement to its market leading LumaGEM Molecular Breast Imaging (MBI) system.

25 Nov 2014

Study: Selenium compounds appear to have beneficial effect on cancer

The immune system is designed to remove things not normally found in the body. Cells undergoing change, e.g. precursors of cancer cells, are therefore normally recognised and removed by the immune system. Unfortunately, the different cancer cells contain mechanisms that block the immune system's ability to recognise them, allowing them to freely continue cancer development.

25 Nov 2014

Cancer Treatment News and Research

Cornerstone Pharmaceuticals initiates CPI-613 Phase I trial in patients with B-cell NHL

Scientists discover new line of defence that cancer cells use to evade cell death

Most elderly women with early-stage breast cancer still receive radiation therapy despite less benefit

AbbVie reports results from venetoclax Phase 2 clinical trial in AML at ASH 2014

Innovative cell therapy shows highly promising results in pediatric patients with ALL

New light-triggered strategy can provide accurate control over aptamer-based therapeutics

Myriad Genetics to highlight clinical data from three Prolaris studies at SUO 2014

Maternal age and successful egg freezing with PGS: an interview with Dr. Santiago Munné

Novartis to highlight advances in blood, breast cancer research at ASH and SABCS 2014

Prostate cancer patients with life expectancies of less than 10 years receive aggressive treatment

Dresden scientists get access to the World's second-fastest computer for cancer research

Researchers use EHRs to uncover hidden drug benefits

TET1 enzyme may be important target for cancer diagnostics, treatment

New research brings personalized cancer vaccine approach one step closer to reality

Scientists make breakthrough in developing new treatment for advanced bladder cancer

Gamma Medica to offer Philips MicroDose SI as complement to LumaGEM MBI system

Study: Selenium compounds appear to have beneficial effect on cancer

EDDA Technology to introduce IQQA-BodyImaging, cloud-based OnDemand service at RSNA 2014

WSU researchers working on new system to reduce negative effects of cancer drugs

Small financial incentives double smoking cessation rates, study reveals

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News